PKCα Peptides Modulating FATP2 Expression for Diabetes Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetes, particularly type 2 diabetes, fail to restore normoglycemia in the long term and have deleterious side effects, with no single drug able to reverse all aspects of the disease.
Innovation Solution
The use of peptides derived from the kinase domain of PKCa, which specifically decrease the expression of Solute Carrier Family 27 Member 2 (SLC27A2) or FATP2 in adipose tissue, thereby improving glucose tolerance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing anti-diabetic medications are used, then glycaemic control is improved, but deleterious side effects occur and effectiveness is lost over time
Solution Approach 1:
The patent employs parameter changes by modifying the amino acid sequence of PKCα peptide to create analogs with improved properties. Specifically, the peptide sequence is optimized to enhance glucose tolerance while reducing side effects, as demonstrated by the improved glucose tolerance test results and reduced adipose tissue mass in treated animals compared to existing therapies
2Reliability
If combination therapy with multiple anti-diabetic agents is used, then glycaemic control is improved, but treatment complexity and side effects increase
Solution Approach 1:
The PKCα peptide analog demonstrates multi-functionality by simultaneously addressing multiple aspects of diabetes pathophysiology through a single agent. The peptide improves glucose tolerance, reduces adipose tissue mass, and decreases hepatic steatosis, thereby replacing the need for combination therapy with multiple specialized agents
3Quantity of substance
If Fatty acid transport protein 2 expression is increased in adipose tissue, then energy storage is improved, but glucose intolerance and diabetes risk increase
Solution Approach 1:
The patent applies parameter changes by modulating FATP2 expression levels in adipose tissue through PKCα peptide treatment. The treatment reduces FATP2 expression to an optimal level that improves glucose tolerance while maintaining energy homeostasis, demonstrating that precise parameter control can resolve the contradiction between energy storage and glucose metabolism
Data Source
AI summary
The present invention relates to peptides for the treatment of diabetes and associated disorders.